ICU Medical (NASDAQ:ICUI) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

A number of other equities analysts also recently commented on ICUI. KeyCorp reduced their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research note on Monday, April 27th. Weiss Ratings raised shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Piper Sandler reduced their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $168.40.

ICU Medical Stock Down 0.9%

Shares of NASDAQ:ICUI opened at $146.60 on Monday. ICU Medical has a 52-week low of $107.00 and a 52-week high of $160.29. The stock has a market cap of $3.66 billion, a P/E ratio of 79.24, a PEG ratio of 2.07 and a beta of 0.77. The business has a fifty day moving average of $132.26 and a two-hundred day moving average of $138.42. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping the consensus estimate of $1.78 by $0.19. The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company’s quarterly revenue was down 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, research analysts expect that ICU Medical will post 6.5 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David C. Greenberg sold 2,424 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ICUI. Millennium Management LLC raised its holdings in shares of ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares during the period. Norges Bank acquired a new position in ICU Medical in the 4th quarter valued at about $58,083,000. Thrivent Financial for Lutherans grew its position in ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after acquiring an additional 285,648 shares in the last quarter. UBS Group AG increased its stake in ICU Medical by 239.8% during the third quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock worth $46,371,000 after purchasing an additional 272,782 shares during the period. Finally, Brown Advisory Inc. purchased a new stake in ICU Medical during the fourth quarter worth about $32,445,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.